What LHRH (luteinizing hormone‑releasing hormone) agonist regimens and dosing are recommended for androgen deprivation therapy in prostate cancer?

LHRH Agonist Regimens for Androgen Deprivation Therapy in Prostate Cancer

LHRH agonists (such as leuprolide, goserelin, or triptorelin) or LHRH antagonists (degarelix) are equally effective as bilateral orchiectomy for achieving castration in prostate cancer, with standard depot formulations administered every 1-3 months depending on the preparation. 1, 2

Standard LHRH Agonist Options and Dosing

The following LHRH agonists are FDA-approved and equally effective 3:

• Leuprolide acetate: Available as 1-month (7.5 mg), 3-month (22.5 mg), 4-month (30 mg), or 6-month (45 mg) depot injections
• Goserelin acetate: Available as 1-month (3.6 mg) or 3-month (10.8 mg) subcutaneous implants
• Triptorelin: Available as 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot injections
• Buserelin: Available in Canada only

The 3-month depot formulations are preferred as they align with routine PSA monitoring visits and optimize patient convenience. 4

Critical Management of Testosterone Flare

An antiandrogen must be administered for 3-4 weeks when initiating LHRH agonist therapy in patients with metastatic disease to prevent testosterone flare and clinical symptom exacerbation. 5, 1 This is a Level III, Grade B recommendation from ESMO guidelines.

The antiandrogen should:

• Start at least 7 days before or simultaneously with the first LHRH agonist injection 1, 2
• Continue for a minimum of 7 days, preferably 3-4 weeks 5
• Be used specifically in patients with overt metastases at risk for flare symptoms 2

LHRH Antagonists as an Alternative

LHRH antagonists (degarelix) provide an alternative that avoids testosterone flare entirely, achieving immediate castration without requiring antiandrogen co-administration. 5, 6

• Degarelix dosing: 240 mg loading dose (two 120 mg subcutaneous injections), followed by 80 mg monthly maintenance doses 7, 8
• Achieves castrate testosterone levels within 3 days without surge 7
• Main disadvantage: requires monthly administration versus quarterly options with agonists 8

Monitoring and Target Testosterone Levels

The target castrate testosterone level is <50 ng/dL (<1.7 nmol/L), which should be verified if PSA rises or disease progresses. 9

• Routine testosterone monitoring is not recommended for most patients 4
• PSA levels remain the primary monitoring tool 1, 4
• Consider testosterone measurement in selected cases: rising PSA despite therapy, doubt about medication administration/absorption, or suspected treatment failure 4

Important caveat: Some evidence suggests individual variation in duration of testosterone suppression, with studies showing 3-month depot formulations maintaining castrate levels for median 6 months in some patients 10, 11. However, standard dosing intervals should be maintained in routine practice.

Combined Androgen Blockade: Not Recommended

Combined androgen blockade (LHRH agonist plus continuous antiandrogen) provides minimal to no survival benefit over castration alone and is not recommended. 5, 1, 6

• Meta-analyses show at most a small statistical benefit (5-year survival 25.4% vs 23.6%, p=0.11) 6
• Increases side effects including diarrhea, liver dysfunction, and hematologic toxicity 12
• The modest potential benefit does not justify added cost and toxicity 6

Continuous vs. Intermittent ADT

Continuous ADT is the standard of care for metastatic hormone-naïve prostate cancer. 5

Intermittent ADT:

• Not recommended outside clinical trials for metastatic disease 5
• May be considered only for patients with significant intolerance to continuous therapy 5
• Non-inferiority was not established in the SWOG 9346 trial (median survival 5.8 vs 5.1 years, HR 1.1) 6
• Some quality-of-life benefits (erectile function, mental health) but requires close monitoring 1

Practical Implementation Algorithm

1. Confirm indication: Metastatic hormone-naïve prostate cancer requiring immediate ADT
2. Choose castration method: LHRH agonist 3-month depot (preferred for convenience) or LHRH antagonist (if flare is a concern)
3. If using LHRH agonist: Start antiandrogen 7 days before or simultaneously, continue 3-4 weeks
4. Verify castration: Check testosterone at 3-4 weeks to confirm <50 ng/dL (optional but reasonable for first dose)
5. Monitor with PSA: Every 3 months aligned with depot administration
6. Continue indefinitely: Even after progression to castration-resistant disease 9

Common Pitfalls to Avoid

• Failing to use antiandrogen coverage with LHRH agonists in metastatic disease—this can cause dangerous symptom flare 5, 1
• Using combined androgen blockade routinely—adds toxicity without meaningful benefit 6
• Stopping ADT when disease becomes castration-resistant—ADT should continue indefinitely 9
• Using antiandrogen monotherapy as primary treatment—inferior to castration 1, 3